-+ 0.00%
-+ 0.00%
-+ 0.00%

Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

Benzinga·09/25/2026 16:26:02
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.